Abstracts tagged "Myositis and outcome measures"

Abstract Number: 878 • 2018 ACR/ARHP Annual Meeting
IFN Level Assessed By Ultrasensitive Detection Technology in Myositis Patient: A Promising Biomarker of Disease Activity in Dermatomyositis and Anti-Synthetase Syndrome
Loïs BOLKO^1,2, Ségolène Toquet³, Océane Landon-Cardinal⁴, Karim DORGHAM⁵, Celine Anquetil⁶, Darragh Duffy⁷, Nadège WESNER⁸, Damien Amelin⁹, Gaëlle DZANGUE TCHOUPOU², Perrine Guillaume¹⁰, Aude Rigolet¹¹, Baptiste Hervier¹¹, Mathieu Vautier¹¹, Nicolas Champtiaux¹¹, Guy Gorochov¹², Jean-Hugues Salmon¹³, Olivier Benveniste¹¹ and Yves Allenbach¹⁴, ¹Rheumatology, CHU Reims, Hôpital Maison Blanche, Reims, France, ²INSERM UMRS974, Pitié-Salpêtrière University Hospital, Paris, France, ³Médecine interne, CHU Reims, Robert debré, Reims, France, ⁴Rhumatologie, Hopital Notre-Dame Montréal, Montreal, QC, Canada, ⁵CIMI, INSERM, Paris, France, ⁶CDR en myologie UMR974,, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, PARIS, France, ⁷Institut Pasteur, Paris, Paris, France, ⁸INSERM UMRS974, Pitié-Salpêtrière University Hospital, paris, France, ⁹Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ¹⁰Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié Salpêtrière, paris, France, ¹¹Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ¹²CIMI, INSERM, paris, France, ¹³Service de Rhumatologie, CHU Reims, Hôpital Maison Blanche, Reims, France, ¹⁴Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Inflammatory idiopathic myopathies (IIM) is a heterogeneous group of disorders ranging from muscle specific auto-immune diseases to systemic ones (dermatomyositis (DM), anti-synthetase syndrome (ASS),…
Abstract Number: 2290 • 2018 ACR/ARHP Annual Meeting
Long Term Follow-up Results of Myositis Patients Treated with H. P. Acthar Gel
Didem Saygin¹, Galina Marder², Chester V. Oddis³, Siamak Moghadam-Kia⁴, Preeya Nandkumar⁵, Zengbiao Qui⁶, Diane Koontz⁷ and Rohit Aggarwal⁸, ¹Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Rheumatology, Northwell Health, Manhasset, NY, ³Division of Rheumatology and Clinical Immunology, Department of Medicine, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine-- Division of Rheumatology, Northwell Health, GREAT NECK, NY, ⁶Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷Internal Medicine Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Although HP Acthar gel is a purified, injectable formulation of full-length adrenocorticotropic hormone approved by the FDA for use in myositis, peer-reviewed data is…
Abstract Number: 2061 • 2013 ACR/ARHP Annual Meeting
Good Inter-Rater Reliability Of Myositis Experts In Assessing Clinical Improvement
Rohit Aggarwal¹, Nicolino. Ruperto², Brian Erman³, Saad Feroz⁴, Jiri Vencovsky⁵, Adam Huber⁶, Sheila K. Oliveira⁷, Angela Pistorio⁸, Clarissa Pilkington⁹, Angelo Ravelli¹⁰, Brian M. Feldman¹¹, Howard Rockette¹², Frederick W. Miller⁴, Peter A. Lachenbruch⁴ and Lisa G. Rider⁴, ¹Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Istituto Gaslini-PRINTO, Genoa, Italy, ³National Institute of Health, Bethesda, DC, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic, ⁶IWK Health Centre, Halifax, NS, Canada, ⁷PRINTO-Istituto Gaslini, Genova, Italy, ⁸PRINTO, Genoa, Italy, ⁹Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ¹⁰Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ¹¹Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ¹²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: IMACS and PRINTO have developed preliminary core set activity measures and definitions of improvement (DOIs) for adult or juvenile dermatomyositis (DM) and polymyositis (PM).…
Abstract Number: 1981 • 2013 ACR/ARHP Annual Meeting
Developing International Consensus Definitions Of Improvement For Adult and Juvenile Dermatomyositis and Polymyositis
Saad Feroz¹, Nicolino. Ruperto², Jiri Vencovsky³, Peter A. Lachenbruch¹, Brian Erman⁴, Adam Huber⁵, Brian M. Feldman⁶, Ingrid E. Lundberg⁷, Angela Pistorio⁸, Howard Rockette⁹, Frederick W. Miller¹, Rohit Aggarwal¹⁰, Lisa G. Rider¹, for The ACR-EULAR Myositis Response Criteria Project Group¹¹, Angelo Ravelli¹², Clarissa Pilkington¹³ and Sheila K. Oliveira¹⁴, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²PRINTO, IRCCS G. Gaslini, Genoa, Italy, ³Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴SRA International, Research Triangle Park, NC, ⁵IWK Health Centre, Halifax, NS, Canada, ⁶Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ⁷Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁸PRINTO, Genoa, Italy, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹¹NIEHS, NIH, Bethesda, MD, ¹²Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ¹³Rheumatology Department, Great Ormond Street Hospital, London, United Kingdom, ¹⁴Pediatric Rheumatology, Instituto de Pediatria e Puericultura Martagão Gesteira (IPPMG) da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
Background/Purpose: IMACS and PRINTO have developed preliminary core set activity measures and definitions of improvement (DOIs). However, these were developed from small and partially retrospective…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].